Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Inclusion Criteria:

   - B-ALL patients must be enrolled on AALL08B1 or APEC14B1 (if open for the
   classification of newly diagnosed ALL patients) prior to treatment and enrollment on
   AALL0932

      - Note: B-LLy patients are not eligible for AALL08B1, and can enroll directly onto
      AALL0932

   - B-ALL patients must have an initial white blood cell count < 50,000/uL

   - Patients must have newly diagnosed National Cancer Institute (NCI) Standard Risk B-ALL
   or B-LLy Murphy stages I or II; patients with Down syndrome are also eligible

      - Note: for B-LLy patients with tissue available for flow cytometry, the criterion
      for diagnosis should be analogous to B-ALL; for tissue processed by other means
      (i.e. paraffin blocks), the methodology and criteria for immunophenotypic
      analysis to establish the diagnosis of B-LLy defined by the submitting
      institution will be accepted

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and NCI requirements for human
   studies must be met

Exclusion Criteria:

   - With the exception of steroid pretreatment (defined below) or the administration of
   intrathecal cytarabine, patients must not have received any prior cytotoxic
   chemotherapy for either the current diagnosis of B-ALL or B-LLy or for any cancer
   diagnosed prior to initiation of protocol therapy on AALL0932

      - Patients receiving prior steroid therapy may be eligible for AALL0932

   - Patients with central nervous system 3 (CNS3) leukemia

      - CNS status must be known prior to enrollment; (Note: the CNS status must be
      determined based on a sample obtained prior to administration of any systemic or
      intrathecal chemotherapy, except for steroid pretreatment); B-LLy patients with
      CNS3 disease are not eligible for this protocol or the COG HR ALL protocol; it is
      recommended that intrathecal cytarabine be administered at the time of the
      diagnostic lumbar puncture; this is usually done at the time of the diagnostic
      bone marrow or venous line placement to avoid a second lumbar puncture; this is
      allowed prior to registration; systemic chemotherapy must begin within 72 hours
      of the first dose of intrathecal therapy

   - B-ALL patients with testicular leukemia are not eligible for AALL0932

   - For B-LLy patients the following additional exclusion criteria apply:

      - T-lymphoblastic lymphoma

      - Morphologically unclassifiable lymphoma

      - Absence of both B-cell and T-cell phenotype markers in a case submitted as
      lymphoblastic lymphoma

      - CNS3-positive disease or testicular involvement

      - M2 (5% - 25% blasts) or M3 (> 25% blasts) marrow

      - Female patients who are pregnant are ineligible

      - Lactating females are not eligible unless they have agreed not to breastfeed
      their infants

      - Female patients of childbearing potential are not eligible unless a negative
      pregnancy test result has been obtained

      - Sexually active patients of reproductive potential are not eligible unless they
      have agreed to use an effective contraceptive method for the duration of their
      study participation